US20040204479A1 - Injectable composition - Google Patents

Injectable composition Download PDF

Info

Publication number
US20040204479A1
US20040204479A1 US10/835,875 US83587504A US2004204479A1 US 20040204479 A1 US20040204479 A1 US 20040204479A1 US 83587504 A US83587504 A US 83587504A US 2004204479 A1 US2004204479 A1 US 2004204479A1
Authority
US
United States
Prior art keywords
acid
citric acid
paclitaxel
citric
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/835,875
Inventor
David Carver
Timothy Prout
Hernita Ewald
Robyn Elliott
Paul Handreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040204479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/835,875 priority Critical patent/US20040204479A1/en
Publication of US20040204479A1 publication Critical patent/US20040204479A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • Paclitaxel is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049.
  • paclitaxel was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft.
  • Paclitaxel is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro.
  • Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly.
  • Paclitaxel employs a different mechanism of action since it appears to shift the equilibrium of polymerimization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules.
  • the interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
  • paclitaxel After extensive preclinical screening in mouse tumor models, paclitaxel entered clinical trials in 1983. Over the past few years, paclitaxel has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefitting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
  • the invention provides a solution containing paclitaxel, cremophor ELTM and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid.
  • Acids in the form of powders for example citric acid
  • those which contain water for example sulfuric acid.
  • the most preferred acid for use in accordance with the present invention is citric acid, but a wide range of acids may be used including the following:
  • Citric acid monohydrous
  • Paclitaxel is usually prepared and administered in a vehicle containing cremophor ELTM (a polyethoxylated castor oil which acts as a solubilizer) and ethanol.
  • cremophor ELTM a polyethoxylated castor oil which acts as a solubilizer
  • BMS Bristol-Myers Squibb
  • the invention essentially teaches addition of an acid to a paclitaxel formulation to adjust its pH into the range 1 to 8, preferable 5 to 7.
  • Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.
  • Cremophor EL was weighed out into the main mixing vessel.
  • Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid.
  • Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes.
  • the paclitaxel was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of paclitaxel.
  • the slurried paclitaxel was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol.
  • Solution 3 was adjusted to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
  • a solution was prepared with the following formulation: Formulation: (Sample 1) Cremophor EL 0.5 mL Citric Acid (Anhydrous) 2.0 mg Paclitaxel 6.0 mg Absolute Alcohol to 1.0 mL The pH of this solution was determined as 6.1.
  • a solution was prepared with the following formulation: Formulation: (Sample 3) Cremophor EL 0.5 mL Paclitaxel 6.0 mg Absolute Ethanol to 1.0 mL pH adjusted to 6.6 with 1.0 M Acetic Acid.

Abstract

A pharmaceutical formulation of paclitaxel and polyethoxylated castor oil is disclosed to be relatively acidified to a pH of less than 8.1 and preferably within a pH range of 5 to 7, inclusively. Ethanol is optionally included in the formulation which is adapted for use in a body for the treatment of cancer. A formulation method is disclosed and includes the step of mixing an acid with a carrier material, such as polyethoxylated castor oil, to form a carrier solution after which paclitaxel is added in an amount such that the resulting pH is less than 8.1 and preferably in a pH range of 5 to 7. Ethanol may optionally be slurried with the paclitaxel before mixing with the carrier solution. A variety of acidifying agents, a preferred one being anhydrous citric acid, are described.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. Ser. No. 09/970,558; filed Oct. 4, 2001; which is a continuation of U.S. Ser. No. 09/563,969, filed May 3, 2000 (now U.S. Pat. No. 6,306,894); which is a continuation of U.S. Ser. No. 09/356,158, filed Jul. 19, 1999 (now U.S. Pat. No. 6,140,359); which is a continuation of U.S. Ser. No. 09/028,906, filed Feb. 24, 1998 (now U.S. Pat. No. 5,972,992); which is a continuation of U.S. Ser. No. 08/979,836, filed Nov. 26, 1997 (now U.S. Pat. No. 5,977,164); which is a divisional of U.S. Ser. No. 08/594,478, filed Jan. 31, 1996 (now U.S. Pat. No. 5,733,888), and which is a continuation of U.S. Ser. No. 07/995,501, filed Dec. 22, 1992, (now abandoned); all of which are hereby incorporated by reference herein in their entirety.[0001]
    • BACKGROUND OF THE INVENTION
  • Paclitaxel is a compound extracted from the bark of a western yew, [0002] Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049.
  • In 1977, paclitaxel was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft. Paclitaxel is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro. Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly. Paclitaxel employs a different mechanism of action since it appears to shift the equilibrium of polymerimization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules. The interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells. [0003]
  • After extensive preclinical screening in mouse tumor models, paclitaxel entered clinical trials in 1983. Over the past few years, paclitaxel has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefitting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck. [0004]
  • For further information, reference may be made to the U.S. National Cancer Institute's Clinical Brochure for Taxol, revised July 1991, and papers presented at the Second National Cancer Institute Workshop on Taxol and Taxus held in Alexandria, Va. USA on Sep. 23-24, 1992.[0005]
    • BRIEF DESCRIPTION OF THE INVENTION
  • It is a disadvantage of the known formulation that the paclitaxel therein degrades, with the result that the shelf life of the formulation is unsatisfactory, and there is therefore a need for a paclitaxel solution of improved stability. [0006]
  • Accordingly, in a general aspect the invention provides a solution containing paclitaxel, cremophor EL™ and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid. [0007]
  • Acids in the form of powders, for example citric acid, are preferred over those which contain water, for example sulfuric acid. The most preferred acid for use in accordance with the present invention is citric acid, but a wide range of acids may be used including the following: [0008]
  • Citric acid—monohydrous [0009]
  • Citric acid—anhydrous [0010]
  • Citric acid—hydrous [0011]
  • Acetic acid [0012]
  • Formic acid [0013]
  • Ascorbic acid [0014]
  • Aspartic acid [0015]
  • Benzene sulphonic acid [0016]
  • Benzoic acid [0017]
  • Hydrochloric acid [0018]
  • Sulphuric acid [0019]
  • Phosphoric acid [0020]
  • Nitric acid [0021]
  • Tartaric acid [0022]
  • Diatrizoic acid [0023]
  • Glutamic acid [0024]
  • Lactic acid [0025]
  • Maleic acid [0026]
  • Succinic acid [0027]
    • DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS
  • Due to its limited solubility in water, Paclitaxel is usually prepared and administered in a vehicle containing cremophor EL™ (a polyethoxylated castor oil which acts as a solubilizer) and ethanol. A commercially available solution supplied by Bristol-Myers Squibb (BMS) is formulated with these components and has a pH of 9.1. [0028]
  • As indicated above, the invention essentially teaches addition of an acid to a paclitaxel formulation to adjust its pH into the range 1 to 8, preferable 5 to 7. [0029]
  • In a preferred procedure adopted by the applicant, which it will be clearly understood is non-limiting, the following steps were carried out: [0030]
  • Mixing Instructions [0031]
  • Solution 1 [0032]
  • Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes. [0033]
  • Solution 2 [0034]
  • Cremophor EL was weighed out into the main mixing vessel. [0035]
  • Solution 3 [0036]
  • Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid. Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes. The paclitaxel was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of paclitaxel. The slurried paclitaxel was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol. Solution 3 was adjusted to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes. [0037]
    • EXAMPLE 1
  • A solution was prepared with the following formulation: [0038]
    Formulation: (Sample 1)
    Cremophor EL     0.5 mL
    Citric Acid (Anhydrous)     2.0 mg
    Paclitaxel     6.0 mg
    Absolute Alcohol to 1.0 mL
    The pH of this solution was determined as 6.1.
  • The stability of this sample was compared with a sample prepared by the formulation stated in the NCI Taxol Clinical brochure (as follows) which had a pH of 9.1. (Sample 2) [0039]
    Sample 2 per mL
    Paclitaxel     6 mg
    Cremophor EL  0.5 mL
    Absolute Alcohol to 1 mL
  • The solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs. [0040]
  • The solutions were stored at 40° C. for 7 (seven) days and the stability results are shown in Table 1. [0041]
    Sample 1 Sample 2
    pH  6.2  9.0
    Potency 96.6 86.7
    Major individual impurity 0.3%  5.1%
    Total impurities 1.0% 12.2%
    Clearly Sample 1 showed significantly increased stability
    over Sample 2.
    • EXAMPLE 2
  • A solution was prepared with the following formulation: [0042]
    Formulation: (Sample 3)
    Cremophor EL     0.5 mL
    Paclitaxel     6.0 mg
    Absolute Ethanol to 1.0 mL
    pH adjusted to 6.6 with 1.0 M Acetic Acid.
  • The solution was filled into clear type I glass 5 mL vials and sealed with rubber bungs. [0043]
  • The solution was stored at 40° C. for 7 days. [0044]
  • The stability results obtained are compared to those seen with Sample 2. [0045]
    Sample 3 Sample 2
    pH  6.7  9.0
    Potency 97.5 86.7
    Major individual impurity 0.3%  5.1%
    Total impurities 2.3% 12.2%
  • Again the significantly superior stability of the formulation according to the invention (Sample 3) is evident. [0046]
  • It will be clearly understood that the invention in its general aspects is not limited to the specific details referred to hereinabove. [0047]

Claims (104)

I claim:
1. A method for formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising the steps of:
mixing an acid with a carrier material to form a first carrier composition; and
mixing paclitaxel with said first carrier composition to form a pharmaceutical paclitaxel composition, such that said pharmaceutical paclitaxel composition retains at least 96.6% of the original paclitaxel potency when said pharmaceutical paclitaxel composition is stored at 40° C. for seven days.
2. The method of claim 1, wherein said first carrier composition comprises polyethoxylated castor oil.
3. The method of claim 2, wherein said first carrier composition further comprises ethanol.
4. The method of claim 1, wherein said acid is an organic acid.
5. The method of claim 1, wherein said acid is a mineral acid.
6. The method of claim 4, wherein said acid is acetic acid.
7. The method of claim 4, wherein said acid is citric acid.
8. The method of claim 7, wherein said citric acid is anhydrous.
9. The method of claim 7, wherein said citric acid is monohydrous.
10. The method of claim 7, wherein said citric acid is hydrous.
11. The method of claim 2, wherein said acid is an organic acid.
12. The method of claim 2, wherein said acid is a mineral acid.
13. The method of claim 11, wherein said acid is acetic acid.
14. The method of claim 11, wherein said acid is citric acid.
15. The method of claim 14, wherein said citric acid is anhydrous.
16. The method of claim 14, wherein said citric acid is monohydrous.
17. The method of claim 14, wherein said citric acid is hydrous.
18. The method of claim 3, wherein said acid is an organic acid.
19. The method of claim 3, wherein said acid is a mineral acid.
20. The method of claim 18, wherein said acid is acetic acid.
21. The method of claim 18, wherein said acid is citric acid.
22. The method of claim 21, wherein said citric acid is anhydrous.
23. The method of claim 21, wherein said citric acid is monohydrous.
24. The method of claim 21, wherein said citric acid is hydrous.
25. A method for formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising the steps of:
mixing an acid with a carrier material to form a first carrier composition; and
mixing paclitaxel with said first carrier composition to form a pharmaceutical paclitaxel composition, such that said pharmaceutical paclitaxel composition comprises no more than 2.3% total impurities when stored at 40° C. for seven days.
26. The method of claim 25, wherein said first carrier composition comprises polyethoxylated castor oil.
27. The method of claim 26, wherein said first carrier composition further comprises ethanol.
28. The method of claim 25, wherein said acid is an organic acid.
29. The method of claim 25, wherein said acid is a mineral acid.
30. The method of claim 28, wherein said acid is acetic acid.
31. The method of claim 28, wherein said acid is citric acid.
32. The method of claim 31, wherein said citric acid is anhydrous.
33. The method of claim 31, wherein said citric acid is monohydrous.
34. The method of claim 31, wherein said citric acid is hydrous.
35. The method of claim 26, wherein said acid is an organic acid.
36. The method of claim 26, wherein said acid is a mineral acid.
37. The method of claim 35 wherein said acid is acetic acid.
38. The method of claim 35, wherein said acid is citric acid.
39. The method of claim 38, wherein said citric acid is anhydrous.
40. The method of claim 38, wherein said citric acid is monohydrous.
41. The method of claim 38, wherein said citric acid is hydrous.
42. The method of claim 27, wherein said acid is an organic acid.
43. The method of claim 27, wherein said acid is a mineral acid.
44. The method of claim 42, wherein said acid is acetic acid.
45. The method of claim 42, wherein said acid is citric acid.
46. The method of claim 45, wherein said citric acid is anhydrous.
47. The method of claim 45, wherein said citric acid is monohydrous.
48. The method of claim 45, wherein said citric acid is hydrous.
49. A method of making an article of manufacture comprising a sealed container and a pharmaceutical paclitaxel formulation contained therein, said method comprising the steps of:
(a) obtaining a sealable container;
(b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that at least 96.6% of the paclitaxel potency is retained when the formulation is stored at 40° C. for seven days;
(c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and
(e) storing said pharmaceutical formulation in said sealed container for at least seven days.
50. The method of claim 49, wherein said first carrier composition comprises polyethoxylated castor oil.
51. The method of claim 50, wherein said first carrier composition further comprises ethanol.
52. The method of claim 49, wherein said acid is an organic acid.
53. The method of claim 49, wherein said acid is a mineral acid.
54. The method of claim 52, wherein said acid is acetic acid.
55. The method of claim 52, wherein said acid is citric acid.
56. The method of claim 55, wherein said citric acid is anhydrous.
57. The method of claim 55, wherein said citric acid is monohydrous.
58. The method of claim 55, wherein said citric acid is hydrous.
59. The method of claim 50, wherein said acid is an organic acid.
60. The method of claim 50, wherein said acid is a mineral acid.
61. The method of claim 59, wherein said acid is acetic acid.
62. The method of claim 59, wherein said acid is citric acid.
63. The method of claim 62, wherein said citric acid is anhydrous.
64. The method of claim 62, wherein said citric acid is monohydrous.
65. The method of claim 62, wherein said citric acid is hydrous.
66. The method of claim 51, wherein said acid is an organic acid.
67. The method of claim 51, wherein said acid is a mineral acid.
68. The method of claim 66, wherein said acid is acetic acid.
69. The method of claim 66, wherein said acid is citric acid.
70. The method of claim 69, wherein said citric acid is anhydrous.
71. The method of claim 69, wherein said citric acid is monohydrous.
72. The method of claim 69, wherein said citric acid is hydrous.
73. A method of making an article of manufacture comprising a sealed container and a pharmaceutical paclitaxel formulation contained therein, said method comprising the steps of:
(a) obtaining a sealable container;
(b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that the formulation comprises no more than 2.3% total impurities when said formulation is stored at 40° C. for seven days;
(c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and
(e) storing said pharmaceutical formulation in said sealed container for at least seven days.
74. The method of claim 73, wherein said first carrier composition comprises polyethoxylated castor oil.
75. The method of claim 74, wherein said first carrier composition further comprises ethanol.
76. The method of claim 73, wherein said acid is an organic acid.
77. The method of claim 73, wherein said acid is a mineral acid.
78. The method of claim 76, wherein said acid is acetic acid.
79. The method of claim 76, wherein said acid is citric acid.
80. The method of claim 79, wherein said citric acid is anhydrous.
81. The method of claim 79, wherein said citric acid is monohydrous.
82. The method of claim 79, wherein said citric acid is hydrous.
83. The method of claim 74, wherein said acid is an organic acid.
84. The method of claim 74, wherein said acid is a mineral acid.
85. The method of claim 83, wherein said acid is acetic acid.
86. The method of claim 83, wherein said acid is citric acid.
87. The method of claim 86, wherein said citric acid is anhydrous.
88. The method of claim 86, wherein said citric acid is monohydrous.
89. The method of claim 86, wherein said citric acid is hydrous.
90. The method of claim 75, wherein said acid is an organic acid.
91. The method of claim 75, wherein said acid is a mineral acid.
92. The method of claim 90, wherein said acid is acetic acid.
93. The method of claim 90, wherein said acid is citric acid.
94. The method of claim 93, wherein said citric acid is anhydrous.
95. The method of claim 93, wherein said citric acid is monohydrous.
96. The method of claim 93, wherein said citric acid is hydrous.
97. A method for formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising
obtaining a composition consisting essentially of paclitaxel, polyethoxylated castor oil, ethanol, and an acid, said acid being in sufficient amount such that the paclitaxel stability of said composition is improved as compared to the paclitaxel stability of an identical composition without said acid; and
sealing said acid-containing paclitaxel composition in a container, wherein said pharmaceutical acid-containing paclitaxel composition retains at least 97.5% of the original paclitaxel potency when stored at 40° C. for 7 days.
98. The method of claim 97, wherein said acid is an organic acid.
99. The method of claim 97, wherein said acid is a mineral acid.
100. The method of claim 98, wherein said acid is acetic acid.
101. The method of claim 98, wherein said acid is citric acid.
102. The method of claim 101, wherein said citric acid is anhydrous.
103. The method of claim 101, wherein said citric acid is monohydrous.
104. The method of claim 101, wherein said citric acid is hydrous.
US10/835,875 1992-11-27 2004-04-29 Injectable composition Abandoned US20040204479A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/835,875 US20040204479A1 (en) 1992-11-27 2004-04-29 Injectable composition

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
AUPL607492 1992-11-27
AU6074 1992-11-27
US99550192A 1992-12-22 1992-12-22
US08/594,478 US5733888A (en) 1992-11-27 1996-01-31 Injectable composition
US08/979,836 US5977164A (en) 1992-11-27 1997-11-26 Stabilized pharmaceutical composition
US09/028,906 US5972992A (en) 1992-11-27 1998-02-24 Injectable composition
US09/356,158 US6140359A (en) 1992-11-27 1999-07-19 Injectable composition
US09/563,969 US6306894B1 (en) 1992-11-27 2000-05-03 Injectable composition
US09/970,558 US6770670B2 (en) 1992-11-27 2001-10-04 Injectable composition
US10/835,875 US20040204479A1 (en) 1992-11-27 2004-04-29 Injectable composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/970,558 Continuation US6770670B2 (en) 1992-11-27 2001-10-04 Injectable composition

Publications (1)

Publication Number Publication Date
US20040204479A1 true US20040204479A1 (en) 2004-10-14

Family

ID=25644377

Family Applications (7)

Application Number Title Priority Date Filing Date
US08/594,478 Expired - Lifetime US5733888A (en) 1992-11-27 1996-01-31 Injectable composition
US08/979,836 Expired - Lifetime US5977164A (en) 1992-11-27 1997-11-26 Stabilized pharmaceutical composition
US09/028,906 Expired - Lifetime US5972992A (en) 1992-11-27 1998-02-24 Injectable composition
US09/356,158 Expired - Fee Related US6140359A (en) 1992-11-27 1999-07-19 Injectable composition
US09/563,969 Expired - Fee Related US6306894B1 (en) 1992-11-27 2000-05-03 Injectable composition
US09/970,558 Expired - Fee Related US6770670B2 (en) 1992-11-27 2001-10-04 Injectable composition
US10/835,875 Abandoned US20040204479A1 (en) 1992-11-27 2004-04-29 Injectable composition

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US08/594,478 Expired - Lifetime US5733888A (en) 1992-11-27 1996-01-31 Injectable composition
US08/979,836 Expired - Lifetime US5977164A (en) 1992-11-27 1997-11-26 Stabilized pharmaceutical composition
US09/028,906 Expired - Lifetime US5972992A (en) 1992-11-27 1998-02-24 Injectable composition
US09/356,158 Expired - Fee Related US6140359A (en) 1992-11-27 1999-07-19 Injectable composition
US09/563,969 Expired - Fee Related US6306894B1 (en) 1992-11-27 2000-05-03 Injectable composition
US09/970,558 Expired - Fee Related US6770670B2 (en) 1992-11-27 2001-10-04 Injectable composition

Country Status (12)

Country Link
US (7) US5733888A (en)
EP (4) EP0835657B1 (en)
JP (1) JP2880292B2 (en)
AT (2) ATE169216T1 (en)
AU (1) AU5612694A (en)
CA (2) CA2149150C (en)
DE (2) DE69320206T2 (en)
DK (2) DK0674510T3 (en)
ES (2) ES2224200T3 (en)
GR (1) GR3027724T3 (en)
PT (1) PT835657E (en)
WO (2) WO1994012031A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
US20190388335A1 (en) * 2014-09-17 2019-12-26 Epizyme, Inc. Injectable formulations for treating cancer

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69320206T2 (en) * 1992-11-27 1999-02-11 Napro Biotherapeutics Inc INJECTABLE COMPOSITION CONTAINING PACLITAXEL
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (en) * 1994-09-28 1996-07-05 Bristol Myers Squibb Co Stabilization solvent, pharmaceutical composition containing it, and process for its preparation.
NL9500340A (en) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Stabilized paclitaxel solution and pharmaceutical preparation containing said solution
DE19536165A1 (en) * 1995-09-28 1997-04-03 Basf Ag Process for cleaning alkoxylated fats
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CN1245423A (en) 1996-12-30 2000-02-23 巴特勒纪念研究院 Formulation and method for treating neoplasms by inhalation
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BE1011216A3 (en) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Pharmaceutical form for the administration of paclitaxel, method of preparation of a composition paclitaxel ready to employment and use thereof.
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
WO2000023070A1 (en) 1998-10-20 2000-04-27 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
KR100856353B1 (en) 1999-05-14 2008-09-04 니리어스 파마슈티컬즈, 인크. Novel interleukin-1 and tumor necrosis factor-?modulators, syntheses of said modulators and methods of using said modulators
DE19925211B4 (en) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit for the preparation of a formulation of paclitaxel
CO5271755A1 (en) * 2000-01-20 2003-04-30 Baker Norton Pharma PURIFICATION OF POLYOXYETHYLED CASTOR OILS WITH ACTIVATED CARBON
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
ATE439441T1 (en) 2000-02-23 2009-08-15 Life Technologies Corp MODIFIED FLUORESCENT PROTEINS
JP4922507B2 (en) * 2000-08-10 2012-04-25 武田薬品工業株式会社 Pharmaceutical composition
EP1310248A4 (en) 2000-08-10 2008-05-21 Takeda Pharmaceutical Pharmaceutical composition
JP4395549B2 (en) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Marine actinomycete taxa for the discovery of drugs and fermentation products
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
EP1379231A2 (en) 2001-04-06 2004-01-14 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (en) * 2001-09-10 2007-11-08 주식회사 중외제약 Injectable composition of paclitaxel
JP2005515187A (en) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド Process for the preparation of pharmaceutical compositions using polyoxyethylated castor oil
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2003053350A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
CZ294371B6 (en) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilized pharmaceutical composition based on polyoxyethylated castor oil and process for preparing thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1530465B2 (en) 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ATE374767T1 (en) * 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc DEHYDROPHENYLAHISTINES AND ANALOGUES THEREOF AND A METHOD FOR PRODUCING DEHYDROPHENYLAHISTINES AND ANALOGUES THEREOF
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
WO2004043390A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
EP1606065A4 (en) * 2003-02-11 2010-09-29 Univ Northwestern Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
KR20060026052A (en) * 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
PL2441767T3 (en) * 2003-06-20 2015-11-30 Univ California Salinosporamides and methods for use thereof
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
PT1694660E (en) * 2003-12-12 2009-07-16 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
BRPI0506535A (en) * 2004-01-23 2007-02-27 Nereus Pharmaceuticals Inc Bisindole pyrroles useful as antimicrobial agents
KR20050099311A (en) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) Composition for injection comprising anticancer drug
EP2025679A3 (en) 2004-04-30 2009-07-08 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7361683B2 (en) 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
DK1830838T3 (en) 2004-12-03 2013-01-21 Dana Farber Cancer Inst Inc Compositions and Methods for Treating Neoplastic Diseases
KR20060121721A (en) * 2005-05-23 2006-11-29 주식회사 중외제약 Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
EP2311795A3 (en) 2005-07-21 2011-12-28 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators
SI3311805T1 (en) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP1928435B8 (en) 2005-08-31 2019-03-20 Abraxis BioScience, LLC Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof
BRPI0600194A (en) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A docetaxel-containing pharmaceutical compositions and a degradation inhibitor and process for obtaining same
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
FR2912745A1 (en) * 2007-02-19 2008-08-22 Centre Nat Rech Scient NEW INDOLE-DERIVED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (en) * 2008-02-29 2011-08-02 동아제약주식회사 Single liquid stable pharmaceutical composition containing docetaxel
MX2010012341A (en) 2008-05-12 2010-12-06 Nereus Pharmaceuticals Inc Salinosporamide derivatives as proteasome inhibitors.
ES2344674B1 (en) * 2008-08-07 2011-06-29 Gp Pharm, S.A. INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS.
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) * 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (en) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc Taxane pro-emulsion formulations and methods making and using the same
NZ603828A (en) 2010-05-03 2015-09-25 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
EP2691075A1 (en) 2011-03-29 2014-02-05 Sanofi Otamixaban formulations with improved stability
EP2731938A4 (en) * 2011-07-11 2014-12-24 Biolyse Pharma Corp Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
CN106794986A (en) 2014-09-02 2017-05-31 布平德尔·辛格 Deuterate or non-deuterate molecule and pharmaceutical preparation
EP3912620A1 (en) 2014-10-08 2021-11-24 Pacific Northwest Research Institute Methods and compositions for increasing the potency of antifungal agents
MX2017011374A (en) 2015-03-06 2018-01-23 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation.
BR112017018964A2 (en) 2015-03-06 2018-05-22 Beyondspring Pharmaceuticals Inc use of plinabulin and methods to treat brain tumor
ES2910035T3 (en) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Plinabulin Compositions
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
CN108778267A (en) 2016-02-08 2018-11-09 万春药业公司 Including the composition of Tucaresol or its analog
KR20190015361A (en) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. Compositions and methods for reducing neutropenia
JP2020503363A (en) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Tubulin binding compounds and their therapeutic use
CN110381938A (en) 2017-02-01 2019-10-25 大连万春布林医药有限公司 The method for reducing neutrophil leucocyte deficiency disease
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP7350015B2 (en) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Compositions and methods for reducing thrombocytopenia due to administration of plinabulin
JP2021519367A (en) 2018-03-28 2021-08-10 ハーバライフ・インターナショナル・オブ・アメリカ・インコーポレイテッド Acetylation of polysaccharides
MX2021004128A (en) * 2018-10-16 2021-06-15 US Nano Food & Drug INC Intratumor injection formulation.
AU2021257738A1 (en) 2020-04-13 2022-05-19 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864370A (en) * 1971-08-06 1975-02-04 Ajinomoto Kk Method of refining crude synthetic fatty acids
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
US5391385A (en) * 1990-02-15 1995-02-21 The Pq Corporation Method of frying oil treatment using an alumina and amorphous silica composition
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5504102A (en) * 1993-09-29 1996-04-02 Bristol-Myers Squibb Company Stabilized pharmaceutical composition and stabilizing solvent
US5733888A (en) * 1992-11-27 1998-03-31 Napro Biotherapeutics, Inc. Injectable composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
TW223634B (en) * 1991-03-18 1994-05-11 Kingston David G I
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864370A (en) * 1971-08-06 1975-02-04 Ajinomoto Kk Method of refining crude synthetic fatty acids
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5391385A (en) * 1990-02-15 1995-02-21 The Pq Corporation Method of frying oil treatment using an alumina and amorphous silica composition
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
US5733888A (en) * 1992-11-27 1998-03-31 Napro Biotherapeutics, Inc. Injectable composition
US5972992A (en) * 1992-11-27 1999-10-26 Napro Biotherapeutics, Inc. Injectable composition
US5977164A (en) * 1992-11-27 1999-11-02 Napro Biotherapeutics, Inc. Stabilized pharmaceutical composition
US6140359A (en) * 1992-11-27 2000-10-31 Napro Biotherapeutics, Inc. Injectable composition
US6306894B1 (en) * 1992-11-27 2001-10-23 Napro Biotherapeutics, Inc. Injectable composition
US6770670B2 (en) * 1992-11-27 2004-08-03 Napro Biotherapeutics, Inc. Injectable composition
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5504102A (en) * 1993-09-29 1996-04-02 Bristol-Myers Squibb Company Stabilized pharmaceutical composition and stabilizing solvent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
US20210353661A1 (en) * 2013-03-15 2021-11-18 Epizyme, Inc. Injectable formulations for treating cancer
US20190388335A1 (en) * 2014-09-17 2019-12-26 Epizyme, Inc. Injectable formulations for treating cancer

Also Published As

Publication number Publication date
US6306894B1 (en) 2001-10-23
ATE169216T1 (en) 1998-08-15
DK0835657T3 (en) 2005-01-10
WO1994012030A1 (en) 1994-06-09
US20030065022A1 (en) 2003-04-03
ATE274347T1 (en) 2004-09-15
US6770670B2 (en) 2004-08-03
US6140359A (en) 2000-10-31
EP0674510B1 (en) 1998-08-05
JP2880292B2 (en) 1999-04-05
DE69320206D1 (en) 1998-09-10
CA2149150C (en) 2000-08-01
EP0674510A1 (en) 1995-10-04
CA2149150A1 (en) 1994-06-09
EP0835657A1 (en) 1998-04-15
JPH08503945A (en) 1996-04-30
DE69320206T2 (en) 1999-02-11
ES2224200T3 (en) 2005-03-01
AU5612694A (en) 1994-06-22
EP1500393A1 (en) 2005-01-26
DK0674510T3 (en) 1999-05-10
CA2308082A1 (en) 1994-06-09
EP0674510A4 (en) 1995-08-12
PT835657E (en) 2004-11-30
EP0835657B1 (en) 2004-08-25
DE69333605T2 (en) 2005-02-03
US5972992A (en) 1999-10-26
EP1384474A1 (en) 2004-01-28
US5733888A (en) 1998-03-31
GR3027724T3 (en) 1998-11-30
WO1994012031A1 (en) 1994-06-09
ES2119996T3 (en) 1998-10-16
US5977164A (en) 1999-11-02
DE69333605D1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
US6770670B2 (en) Injectable composition
WO1994012198A1 (en) Injectable taxol composition
US4310543A (en) Prostaglandin compositions
JP2009524700A (en) Pharmaceutical composition containing docetaxel and degradation inhibitor and method for producing the pharmaceutical composition
CA2388613A1 (en) New and improved formulation for paclitaxel
JP4805599B2 (en) Paclitaxel aqueous injection solution and preparation method thereof
AU2002351169B2 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
JPH10507177A (en) Parenteral pharmaceutical composition comprising GF120918A
JP2011529930A (en) Injectable taxane pharmaceutical composition
EP0452697A1 (en) Stabilizer for 4-ethyl-2-hydroxyimino5-nitro-3-hexenamide-containing preparation and stabilizing method therefor
JP6292267B2 (en) Docetaxel formulation
EP0236280B1 (en) Injectable pharmaceutical formulations of active principles having general anaesthetic activity
JP2018115178A (en) Docetaxel formulation
GB2388025A (en) Kit for preparing a formulation of paclitaxel
WO2005044257A1 (en) Discodermolide compositions
JPH07267875A (en) Liquid preparation containing high concentration of aureobasidin

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION